Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Buys 35,433 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 35,433 shares of the firm’s stock in a transaction dated Friday, March 13th. The stock was bought at an average price of $24.88 per share, with a total value of $881,573.04. Following the completion of the acquisition, the insider directly owned 675,018 shares of the company’s stock, valued at approximately $16,794,447.84. This represents a 5.54% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, March 16th, Tcg Crossover Gp Ii, Llc bought 1,190 shares of Surrozen stock. The shares were purchased at an average cost of $24.99 per share, for a total transaction of $29,738.10.
• On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The stock was purchased at an average price of $24.99 per share, with a total value of $309,226.26.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc purchased 1,093 shares of Surrozen stock. The shares were purchased at an average cost of $23.86 per share, with a total value of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The shares were purchased at an average price of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The stock was purchased at an average price of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The shares were purchased at an average cost of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The shares were purchased at an average cost of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Stock Up 1.2%

Surrozen stock traded up $0.29 during midday trading on Monday, hitting $25.50. The company’s stock had a trading volume of 33,763 shares, compared to its average volume of 112,361. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $29.59. The company has a market capitalization of $218.56 million, a PE ratio of -1.14 and a beta of 0.53. The stock’s 50-day moving average price is $23.46 and its 200-day moving average price is $18.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares during the period. Persistent Asset Partners Ltd acquired a new position in Surrozen in the 4th quarter worth approximately $99,000. Citadel Advisors LLC boosted its stake in Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the period. Marshall Wace LLP purchased a new position in Surrozen during the 4th quarter worth approximately $247,000. Finally, Geode Capital Management LLC raised its stake in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares during the period. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Cantor Fitzgerald started coverage on shares of Surrozen in a report on Thursday, February 19th. They set an “overweight” rating and a $40.00 target price for the company. Wall Street Zen upgraded Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.